But regulation is not keeping up
Try supplementation or IV
EVEXIAS Denver Can Help
Key drivers: Tissue damage Microtears, fraying, articular cartilage degeneration, compromised ligament/tendon integrity Chemical irritation Pro-inflammatory cytokines (e.g., TNF-, IL-1), acidotic microenvironments, enzymatic degradation of extracellular matrix Mechanical stress Joint instability, aberrant gait or movement patterns, maldistributed forces, shearing and compressive overload Neural sensitization Peripheral nociceptor upregulation, angry free nerve endings firing continuously, dorsal horn wind-up, central sensitization increasing pain output Lifestyle and systemic factors Poor sleep, nutrition imbalances, metabolic stress, psychosocial load, smoking, inactivity Age-related decline Reduced native stem cell pool and vigor, decreased reparative signaling, diminished angiogenic responses, slower collagen remodeling Why traditional symptom management often falls short: NSAIDs and steroids Useful for acute severe pain but can impair cartilage health (chondrotoxicity), weaken tendons/ligaments, disrupt gut barrier, and fail to resolve root mechanical and immune drivers One-off procedures Arthroscopic clean-outs for degenerative arthritis show limited long-term benefit compared to sham in many cases
The cost calculator helps plan sustainable protocols, while the stack calculator organizes complex multi-peptide approaches
KLOW is a four-peptide research blend that combines 10 mg of BPC-157, 50 mg of GHK-Cu, 10 mg of TB-500 (thymosin beta-4 fragment) and 10 mg of KPV in one lyophilised vial, for 80 mg of total peptide content
